Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.

@article{Stoch2013OdanacatibAS,
  title={Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.},
  author={Selwyn Aubrey Stoch and Stefan C Zajic and Julie A. Stone and Deborah L. Miller and Lucas M Van Bortel and Kenneth C. Lasseter and Barnali Pramanik and Caroline Cilissen and Qi Liu and Lida Liu and Boyd B. Scott and Deborah Panebianco and Yu Ding and Keith Gottesdiener and John J. Wagner},
  journal={British journal of clinical pharmacology},
  year={2013},
  volume={75 5},
  pages={1240-54}
}
AIMS To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of odanacatib (ODN), a cathepsin K inhibitor, in humans. METHODS Two double-blind, randomized, placebo-controlled, single oral dose studies were performed with ODN (2-600 mg) in 44 healthy volunteers (36 men and eight postmenopausal women). RESULTS Adverse experiences (AEs… CONTINUE READING